Special Issue

Topic: Emerging Biomarkers for Early Diagnosis and Prognosis of Hepatocellular Carcinoma

ISSN 2454-2520 (Online) 2394-5079 (Print)

Submission deadline: 29 Feb 2024

Guest Editor(s)

Prof. Xiao Xu, MD, PhD

Associate dean of school of medicine, President of Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China;

The Yangtze River Scholar Distinguished Professor of the Ministry of Education, winner of the National Science Fund for Distinguished Young Scholars and winner of Ten Thousand Talent Program.Qiushi Distinguished Professor of Zhejiang University;

Winner of China Cancer Young Scientist Award and Wu Mengchao Medical Youth Fund Award;

The vice chairman and head of the Liver Transplantation Group of the Organ Transplantation Branch of the Chinese Medical Association, the vice president and director general of the Organ Transplantation Branch of the Chinese Medical Doctor Association, and the vice chairman of the tumor Precision Therapy Professional Committee of the Chinese Anti-Cancer Association.

Special Issue Introduction

Hepatocellular carcinoma (HCC) ranks as the sixth most common cancer and the third leading cause of cancer-related deaths in the world. Particularly in China, it stands as the malignant tumor with the highest mortality rate among adult males under 60 years old in China. Reports indicate that 905,700 people suffer from liver cancer worldwide. HCC accounts for 75%-85% of primary liver cancer cases, posing a heavy disease burden globally. Chronic liver diseases, particularly hepatitis B and C, along with exposure to toxins like aflatoxin and certain metabolic diseases, significantly contribute to the development of HCC. Typically, patients diagnosed with HCC are already in an advanced stage, underscoring the critical need for early detection and diagnosis to facilitate timely intervention and treatment. Despite the principle of administering systemic treatment to HCC patients, the overall response rate remains notably low, leading to a poor prognosis, and the estimated 5-year overall survival rates for HCC are less than 20%. Although great progress has been made in the research of HCC, its morbidity and mortality continue to rise. Therefore, further investigation and validation of biomarkers for early diagnosis and prognosis of HCC are imperative.

This Special Issue of Hepatoma Research aims to engage leading experts in discussing emerging biomarkers for early diagnosis and prognosis of HCC.

Potential topics include, but are not limited to, the following:
1. Screening of emerging diagnostic biomarkers for HCC;
2. Screening of emerging prognostic biomarkers for HCC;
3. Establishment of early diagnosis models for HCC;
4. Establishment of precise prognosis models for HCC;
5. Optimization of existing diagnosis models for HCC;
6. Optimization of existing prognosis models for HCC;
7. HCC multi-omics study, including genomics, transcriptomics, proteomics, metabolomics, and so on;
8. Diagnostic biomarkers for regional treatment for HCC, including liver resection, liver transplantation, and so on;
9. Prognostic biomarkers for regional treatment for HCC, including liver resection, liver transplantation, and so on;
10. Diagnostic biomarkers for systematic treatment for HCC, including immunotherapies, targeted therapies, and so on;
11. Prognostic biomarkers for systematic treatment for HCC, including immunotherapies, targeted therapies, and so on.

Submission Deadline

29 Feb 2024

Submission Information

For Author Instructions, please refer to https://www.oaepublish.com/hr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=hr&SpecialIssueId=hr231124
Submission Deadline: 29 Feb 2024
Contacts: Eric Zhang, Assistant Editor, scienceeditor@hrpublishing.net

Published Articles

Coming soon